Friday 6 November 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
120.06
4.05
−3.26%
Follow HAE
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 6 | 7 |
+8 more TTM periods Free account |
| 11.89% | 11.20% | 12.03% | 19.30% | ||
| 4.28% | 3.99% | 4.02% | 6.99% | ||
ROIC |
6.31% | 5.62% | 5.53% | 10.69% | |
Return on Tangible Assets |
12.05% | 11.31% | 11.34% | 25.03% | |
Average Days of Receivables |
59.39 | 58.33 | 59.33 | 54.19 | |
Free Cash Flow per Share |
7.58 | 6.45 | 5.55 | 6.65 | |
Free Cash Flow |
344.93 | 292.53 | 261.82 | 311.38 | |
Capital Expenditures |
— | (35.62) | (31.40) | (27.46) | |
| Other line items | |||||
Cash ROIC |
15.17% | 13.12% | 11.58% | 14.19% | |
Accounts Receivable Turnover |
6.40 | 6.49 | 6.36 | 6.47 | |
Accounts Payable Turnover |
8.37 | 10.82 | 9.26 | 9.60 | |
Inventory Turnover |
1.74 | 1.66 | 1.63 | 1.57 | |
Average Days of Payables |
46.85 | 37.13 | 34.10 | 33.17 | |
Days of Inventory on Hand |
199.46 | 202.14 | 204.64 | 218.78 | |
Tax Rate |
(0.27) | (0.26) | (0.24) | (0.23) | |
Research and Development Expense of Revenue |
4.47% | 4.42% | 4.48% | 4.83% | |
Selling, General and Administrative Expense of Revenue |
33.81% | 33.33% | 33.16% | 33.12% | |
Share Based Compensation of Revenue |
2.64% | 2.50% | 2.54% | 2.40% | |
Interest Coverage |
5.06 | 5.36 | 5.46 | 10.49 | |
Operating CF/Net income |
3.32 | 3.41 | 3.01 | 1.93 | |
Depreciation/Fixed assets |
0.00 | 0.37 | 0.38 | 0.41 | |
Capex/Depreciation |
— | (0.31) | (0.27) | (0.23) | |
Revenue per Share |
30.38 | 29.81 | 28.28 | 28.17 | |
Operating CF per Share |
7.58 | 7.23 | 6.22 | 7.24 | |
Capex per Share |
0.00 | (0.79) | (0.67) | (0.59) | |
Capex to Sales |
0.00 | 0.03 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026